NO20004966D0 - Use of anti-gp-39 antibody in the treatment and / or reversal of lupus and associated kidney disease - Google Patents

Use of anti-gp-39 antibody in the treatment and / or reversal of lupus and associated kidney disease

Info

Publication number
NO20004966D0
NO20004966D0 NO20004966A NO20004966A NO20004966D0 NO 20004966 D0 NO20004966 D0 NO 20004966D0 NO 20004966 A NO20004966 A NO 20004966A NO 20004966 A NO20004966 A NO 20004966A NO 20004966 D0 NO20004966 D0 NO 20004966D0
Authority
NO
Norway
Prior art keywords
lupus
reversal
antibody
treatment
kidney disease
Prior art date
Application number
NO20004966A
Other languages
Norwegian (no)
Other versions
NO20004966L (en
Inventor
Randolph J Noelle
Christopher M Burns
Original Assignee
Dartmouth College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dartmouth College filed Critical Dartmouth College
Publication of NO20004966D0 publication Critical patent/NO20004966D0/en
Publication of NO20004966L publication Critical patent/NO20004966L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
NO20004966A 1998-04-03 2000-10-02 Use of anti-gp-39 antibody in the treatment and / or reversal of lupus and associated kidney disease NO20004966L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5448898A 1998-04-03 1998-04-03
PCT/US1999/007321 WO1999051258A1 (en) 1998-04-03 1999-04-02 USE OF ANTI-gp39 ANTIBODIES FOR TREATMENT AND/OR REVERSAL OF LUPUS AND ASSOCIATED KIDNEY DISEASE

Publications (2)

Publication Number Publication Date
NO20004966D0 true NO20004966D0 (en) 2000-10-02
NO20004966L NO20004966L (en) 2000-12-04

Family

ID=21991433

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004966A NO20004966L (en) 1998-04-03 2000-10-02 Use of anti-gp-39 antibody in the treatment and / or reversal of lupus and associated kidney disease

Country Status (9)

Country Link
EP (1) EP1067954A4 (en)
JP (1) JP2002510643A (en)
KR (1) KR20010072564A (en)
CN (2) CN100352497C (en)
AU (1) AU743824B2 (en)
HU (1) HUP0101689A3 (en)
NO (1) NO20004966L (en)
TW (1) TWI224969B (en)
WO (1) WO1999051258A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41459A (en) 2015-02-03 2017-12-12 Als Therapy Development Inst ANTI-CD40L ANTIBODIES AND METHODS FOR TREATING CD40L ILLNESSES OR DISORDERS
EA201890434A1 (en) 2015-08-05 2018-10-31 Янссен Байотек, Инк. ANTIBODIES TO CD154 AND METHODS OF THEIR APPLICATION
SG10202111207TA (en) 2017-05-24 2021-11-29 Als Therapy Development Inst Therapeutic anti-cd40 ligand antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
IL104684A0 (en) * 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
NZ337072A (en) * 1997-01-10 2000-12-22 Biogen Inc use of an anti-CD40L compounds to inhibit the progression of nephritis, stabilize nephritis or reverse nephritis in a patient with an immune complex disease
AU5623398A (en) * 1997-03-07 1998-09-22 Biogen, Inc. Methods of therapeutic administration of anti-cd40l compounds
WO1999000143A1 (en) * 1997-06-27 1999-01-07 Biogen, Inc. Cd154 blockade therapy for autoimmune diseases

Also Published As

Publication number Publication date
CN1173735C (en) 2004-11-03
HUP0101689A3 (en) 2004-08-30
NO20004966L (en) 2000-12-04
AU3379699A (en) 1999-10-25
EP1067954A1 (en) 2001-01-17
EP1067954A4 (en) 2004-08-18
CN100352497C (en) 2007-12-05
TWI224969B (en) 2004-12-11
JP2002510643A (en) 2002-04-09
CN1757413A (en) 2006-04-12
KR20010072564A (en) 2001-07-31
HUP0101689A2 (en) 2001-08-28
WO1999051258A1 (en) 1999-10-14
AU743824B2 (en) 2002-02-07
CN1303301A (en) 2001-07-11

Similar Documents

Publication Publication Date Title
FI970215A0 (en) Use of droloxifene in the treatment of prostate disease, endometriosis and obesity
NO20034437L (en) Ganglioside-associated recombinant antibodies and their use in the diagnosis and treatment of tumors
NO20024682D0 (en) Combined use of anti-cytokine antibody or antagonists and anti-CD20 in the treatment of B-cell lymphoma
EP1194927A4 (en) SERIOUS AND INSCRIPTIBLE COMBINED MEDIA AND USE IN THE INTERNET APPARATUS OF ELECTRONIC BOOKS
IL200404A (en) Couplings of 191p4d12 (b) protein-binding antibodies and their use in the treatment of cancer
NO991700D0 (en) Benzimidazole-2-carbamates for the treatment of viral infections and cancer
NO20002846D0 (en) Inhalation device and method of the same
EE05507B1 (en) Use of rosuvastatin ZD4522) in the treatment of heterosgococcal family h percolesterolemia
NO983576L (en) Well treatment fluids and methods
NO985196D0 (en) Dispersible macromolecule mixtures and processes for their preparation and use
DE69715482D1 (en) Preparation of 1,1,1,3,3-pentachlorobutane and 1,1,1,3,3-pentafluorobutane
NO20033443D0 (en) Use of CD-2 binding agents in the treatment or prevention of skin disorders
FR2812197B1 (en) USE OF CO IN THE TREATMENT OF INFLAMMATION OF THE UPPER AIRWAYS OR BRONCHIA
HUP0202048A3 (en) Use of alpha1betha1 integrin receptor inhibitors and tgf-betha1 inhibitors in the treatment of kidney disease
NO872302D0 (en) PESTICIDE MIXTURES AND PROCEDURES IN THE PREPARATION OF THESE.
ITTO20001156A0 (en) EQUIPMENT FOR THE DISGREGATION TREATMENT OF BIOLOGICAL SAMPLES AND DISGREGATION DEVICE FOR USE IN SAID EQUIPMENT.
NO991160D0 (en) Sulfate-containing polysaccharides and their applications in medical treatment
NO20001412D0 (en) Compositions and Methods in the Treatment of Respiratory Disorders
NO951825D0 (en) Water based hair treatment preparation and its use
IS2207B (en) Carbocyclic nucleus hemisulfate and its use in the treatment of viral infections
NO20040659L (en) Isoxazolopyridinones and their use in the treatment of Parkinson's disease
GB2328298B (en) Cache performance improvement through the use of early select techniques and pipelining
NO20020207L (en) Biological materials and methods useful in the diagnosis and treatment of disease
NO20004966L (en) Use of anti-gp-39 antibody in the treatment and / or reversal of lupus and associated kidney disease
FI964809A0 (en) In the case of use of the processing unit

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application